廣告
香港股市 已收市

  • 恒指

    16,224.14
    -161.73 (-0.99%)
     

  • 國指

    5,746.61
    -57.25 (-0.99%)
     

  • 上證綜指

    3,065.26
    -8.96 (-0.29%)
     

  • 滬深300

    3,541.66
    -28.14 (-0.79%)
     

  • 美元

    7.8321
    +0.0009 (+0.01%)
     

  • 人民幣

    0.9239
    +0.0002 (+0.02%)
     

  • 道指

    37,986.40
    +211.02 (+0.56%)
     

  • 標普 500

    4,967.23
    -43.89 (-0.88%)
     

  • 納指

    15,282.01
    -319.49 (-2.05%)
     

  • 日圓

    0.0504
    +0.0000 (+0.02%)
     

  • 歐元

    8.3421
    +0.0077 (+0.09%)
     

  • 英鎊

    9.6890
    -0.0500 (-0.51%)
     

  • 紐約期油

    83.24
    +0.51 (+0.62%)
     

  • 金價

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin

    63,853.43
    -1,003.32 (-1.55%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease

Akanksha Bakshi
·1 分鐘文章

  • Roche (OTC: RHHBY) announces collaboration with Eli Lilly and Company (NYSE: LLY) to support the development of its Elecsys Amyloid Plasma Panel (EAPP).

  • The EAPP is a blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease.

  • If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis.

  • Also Read: New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients

  • Roche's Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Phospho-Tau (181P) CSF (pTau181) assays, which identify Alzheimer's pathology in its early symptomatic stage, gained FDA 510(k) clearance in December 2022.

  • Price Action: RHHBY closed higher by 1.37% at $35.62 on Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.